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Abstract—A simple, accurate, and sensitive method for the 
spectrophotometric determination of captopril in bulk and dosage 
forms is reported. The method is based on the bromination of 
captopril with excess solution of n-bromosuccinimide (NBS) in 
HCl acid medium. The excess NBS is pursued by the assessment 
of the residual NBS based on its ability to bleach the rhodamine B 
dye and measuring the absorbance at 555 nm. The amount of NBS 
reacted coincides to the drug content. The different experimental 
parameters influencing the development and stability of the color 
are precisely studied and optimized. Beer’s law is valid within a 
concentration range of 0.3–1.0 μg/mL with a correlation coefficient 
R2 = 0.991. The limit of detection 0.169 μg/mL is attained and 
relative standard deviation values for five replicated measurements 
of 0.3, 0.7, and 1.0 μg/mL captopril were between 0.53% and 
2.03%. No interference is detected from prevalent additives 
found in pharmaceutical preparations. The proposed method is 
profitably put on to the determination of captopril in the tablet 
formulations with mean recoveries 98.91–101.27% and the results 
were statistically confronted with those of a reference method by 
applying Student’s t-and F-test.
Index Terms—Captopril, Indirect determination, 
n-bromosuccinimide, Rhodamine B, Spectrophotometer.
I. Introduction
Hypertension takes place with two-fold the recurrence 
in the diabetic community in comparison with the non-
diabetic community, and more than 50% of patients 
with type 2 diabetes mellitus develop into hypertensive 
(Parving, et al., 1983). Besides, enduring a large risk cause 
for atherosclerosis in large blood vessels, hypertension 
in diabetes contributes to mini-vessel disease and is a 
danger cause for diabetic nephropathy and probably for 
diabetic retinopathy. Investigations have presented that 
angiotensin-converting enzyme (ACE) inhibitors can 
sluggish the development of diabetic nephropathy in patients 
with type 1 or type 2 diabetes with microalbuminuria or 
macroalbuminuria (Phillip and Hall, 2006).
A main thing whither toward preserve the kidney from the 
complexity of diabetes is to manage elevated blood pressure 
destructively, despite the antihypertensive drug types utilized. 
Literature stated that patients with type 1 diabetes and 
antihypertensive drugs such as diuretics, beta-blockers, and 
hydralazine were taken, demonstrating that decreasing blood 
pressure diminishes proteinuria and sluggish the dismiss of renal 
work (Lewis, et al., 1993). A predominance of clue records that 
ACE inhibitors preserve the kidney more than undertake other 
blood pressure suppressing medications, apparently because 
ACE inhibitors particularly reduce the intrarenal pressure.
Patients with type 1 diabetes, albuminuria, and mildly 
impaired creatinine clearance were exposed to a milestone 
study. The ACE inhibitor captopril was diminished the risk 
of a decline in renal function more effectively than did 
other antihypertensive regimens (Lewis, et al., 1993). It 
has been found that captopril is powerful in lowering blood 
pressure and also lowering the risk of macrovascular end 
points. It was confirmed that captopril does not develop any 
important differences in the blood levels of ionized calcium 
or phosphorous ions and that it does not modify the serum 
levels of parathyroid hormone (PTH) and metabolites of 
Vitamin D (Florentin, et al., 2004).
Captopril (1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-
proline) is an inhibitor of ACE, acting directly on the adrenal 
gland to activate the release of aldosterone (Fig. 1). It 
inhibits elevated blood pressure by preventing the enzymatic 
alteration of angiotensin I to angiotensin II. It is a white 
crystalline powder (C9H15NO3S, molar mass 217.29 g/mol) 
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having an essence sulfide-like odor and a melting point 
between 105 and 108°C. Captopril is plainly soluble in 
water or diluted solutions of alkali hydroxides, in alcohols, 
in methylene chloride, or in chloroform (Milan, et al., 2015).
Many methods were available for the determination of 
captopril in various samples including pharmaceutical products. 
The first approaches to captopril determination in biological 
matrix were made by liquid chromatography (LC) and mass 
spectrometry (Salem, et al., 2005, Vancea, et al., 2009).
Captopril is determined in blood, plasma, and urine using 
an investigate method of high-performance LC (HPLC). 
Nevertheless, determination methods of low concentration 
levels of captopril based on oxidation reaction are pursued 
three different oversights: Apply of extra sensitive detection 
method as an alternative to ultraviolet (UV) method such 
as electrochemical method without any derivatization of 
the analyte; detection of a derivatized product of captopril 
that is identified before or after chromatographic separation 
using the UV or fluorescent method; and utilize of pre-
concentration techniques such as liquid-liquid extraction and 
multicolumn switching setup (Florentin, et al., 2004).
Despite the fact that captopril is non-toxic, but appropriate 
caution must be taken because it can cause hypotension when 
overdosed. This result is only expected following ingestion of 
quantities >450 mg/day. Taking medicines of captopril level above 
the accepted value can be harmful to the patient (Jia, et al., 2001). 
Accordingly, there is a sustaining demand for the development of 
new analytical procedures for the determination of captopril in 
pharmaceutical products (Lima, et al., 2016).
HPLC is recognized as a favored analytical technique 
for identification and quantification of most pharmaceutical 
products including captopril (Iqbal, et al., 2015). Disregarding 
that the advantage of HPLC as it is a well-built technology in 
the pharmaceutical field, offering sensitivity and specificity, 
it has defects that include high operation costs, the demand 
for large amounts of samples and solvents, and the formation 
of hazardous wastes such as organic solvents that are costly 
to relinquish and can have significant environmental impacts 
(Safila, et al., 2013).
In the published works, different methods were reported 
for the determination of captopril which include atomic 
absorption spectrometry, spectrophotometry, chemiluminescence, 
LC, amperometry, electrophoresis, and HPLC techniques 
(El-reis, et al., 2000; El-Shanawany, et al., 2014; Zhaofu, et al., 
2017; Fu, et al., 2017, Shafi, et al., 2015; Marcolino-Junior, et al., 
2009; Tomas, et al., 2006; Iqbal, et al., 2015, Zhang, et al., 2020). 
The use of spectrophotometry provides a simple and 
inexpensive technique for the determination of drugs in 
pharmaceutical products. Sensitivity is another important 
characteristic of molecular absorption technique. Besides, the 
large linear concentration ranges make the method interesting 
and versatile for routine analysis of drugs in quality control 
laboratories (Rao, et al., 2012). Most of the reported methods 
were based on the redox reaction of captopril with an excess 
of an oxidizing agent (El-Didamony and Erfan, 2010; 
Skowron and Ciesielski, 2011).
The aim of the present work was, therefore, to use a convenient, 
low cost but sensitive analytical method as spectrophotometer 
for quantification of captopril in pharmaceuticals based on redox 
reaction with n-bromosuccinimide (NBS) and rhodamine B 
dye (RB). The results were compared with the recommended 
method described in the literature.
II. EXPERIMENTAL
A. Apparatus
Molecular absorption spectra were measured using UV-
1000 CECIL 1021 spectrophotometer, UK, with a glass cell of 
1.0 cm optimal path length. LW Scientific Digital Water Bath, 
US, was used to control the temperature of the solution during 
the studies. The studies were accomplished using HPLC system 
of Agilent 1100 controlled by ChemStation Data System. A 
G 1311A quaternary pump and UV detector (VWD-G1314 
A) were supplied with the system. A reverse phase C18 
column (Kromasil 100-5-Phenyl®, 300 mm × 4.6 mm, 5 μm) 
was handling at 25°C and the mobile phase of 0.1 % v/v 
trifluoroacetic acid and acetonitrile at ratio (80:20 v/v) was 
provided during the investigation. The flow rate of 1.5 mL/min 
elute was advised at wavelength 290 nm.
B. Material and Reagent
Captopril was collected from Awamedica Pharmaceutical 
Company (Kurdistan region, Iraq), used as received, the 
purity of which was 99.9%. A solution of 100 μg/mL of 
NBS (from Fluka) was prepared by dissolving 0.1 g of NBS 
(C4H4BrNO2) in small amount of warm water, then diluted 
to 1000 mL with distilled water, and kept in 5°C refrigerator 
until further usage. A dye solution of 100 μg/mL of RB (from 
RIEDEL-DEHAEN) was prepared by dissolving 0.1 g of RB 
in distilled water and diluted to 1000 mL with distilled water 
(the solution is stable for at least 2 weeks). Hydrochloric 
acid, sulfuric acid, nitric acid, and acetic acid (from Scharlau) 
of 1 mol/L solution were prepared, individually. Interfering 
solutions of 500 μg/mL of fructose (from BDH), glucose 
(SCP), lactose (BDH), starch (from Difco), and sucrose 
(from Difco) were prepared individually by dissolving 0.1 g 
of solid compound in 100 ml distilled water.
C. Preparation of Standard and Sample Solution
A stock solution of standard captopril 1000 μg/mL was 
prepared by dissolving 0.1 g of standard captopril powder in 
Fig. 1. Chemical structure of captopril.
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20 mL distilled water with stirring carefully, then the volume 
was completed to 100 mL volumetric flask with the same 
solvent and kept in 5°C refrigerator to remain stable for 28 
days (Pereira and Tam, 1992). Working standard solutions 
were prepared daily by proper dilution of the stock standard 
solution with the same solvent.
All pharmaceutical products of captopril in the local medical 
store are containing 25 mg and two different companies were 
used for the determination (captopril Awa, Erbil, Iraq, and 
Rilcapton, Medochemie-Cyprus). Ten tablets of captopril 
were weighed and crushed for each pharmaceutical company, 
and the sample powder of the two companies was accurately 
weighed individually and placed in a 50.0 mL beaker, then 
dissolved in 30.0 mL of distilled water. The solution was 
stirred for 10 min to increase solubility. Insoluble excipient 
was removed by filtration using Whatman No. 41 membrane 
filter paper. The filtered solution was diluted to 100 mL in a 
volumetric flask with the same solvent.
D. Analytical Procedure
In 25.0 mL volumetric flask, 2.5 mL of NBS (100 μg/mL), 
0.8 mL of HCl (1 mol/L), and adequate captopril standard or 
sample (0.3–1.0 μg/mL) of 100 μg/mL solution were added. 
This mixture was shacked thoroughly and left to stand for 
10 min at 25 ± 2°C. Finally, 2.5 mL of RB (100 μg/mL) was 
added and directly diluted to the mark with distilled water. 
The absorbance was measured against reagent blank prepared 
in similar conditions without captopril at 555 nm.
III. Results and Discussion
Captopril is acting as a reducing agent due to the presence of 
thiol group (- SH) in its structure and the literature explains that 
captopril in aqueous solution undergoes oxidative degradation 
at its thiol function to yield captopril-disulfide (Chenl, et al., 
1995). In this work, the reaction involves two steps (Fig. 2):
(i) Oxidation of the drug (captopril) by excess of NBS reagent, 
generated in sedentary by the action of HCl acid solution on 
captopril-disulfide
(ii) Determination of unreacted oxidant NBS by bleaching the 
color of RB dye in acidic medium (Abdel-Hady, 2013).
The absorption spectrum of the yielded bleaching 2.5 mL 
of (100 μg/mL) RB demonstrated the maximum absorbance 
at 555 nm against the blank solution after 10 min (Fig. 3a). 
The absorbance of individual 0.7 μg/mL captopril showed 
dropping at the same wavelength (Fig. 3b), whereas no 
significant absorbance was recorded for the blank reagent of 
NBS and RB dye (Fig. 3c).
A. Optimum of Experimental Conditions
The reaction conditions along with the different 
experimental parameters influencing the color development 
and stability of the dye were laboriously examined and 
optimized for the quantitative determination of captopril in 
bulk and the tablet dosage forms.
Selection of type and acid concentration
The reaction of 0.7 μg/mL captopril with 2.5 mL of 
(100 μg/mL) solution of each of NBS and RB dye was tested 
in 1 mol/L of HCl, HNO3, H2SO4, and CH3COOH solutions, 
individually. The results demonstrated that the reaction is 
suitable in hydrochloric acid medium (Fig. 4a). A 1 mol/L 
HCl solution was found to be sufficient for the oxidation of 
captopril as well as the bleaching of RB dye. The variation 
in HCl volumes indicated that highest absorbance was 
observed with 0.8 mL of 1 mol/L HCl, subsequent studies 
were performed with this volume and concentration of HCl 
(Fig. 4b).
Sequence of addition
The sequence of addition of 2.5 mL (100 μg/mL) NBS 
oxidant, drug solution, 2.5 mL (100 μg/mL) RB dye, and 
0.8 mL (1 mol/L) HCl was studied through bleaching the 
color of RB dye and measuring its absorbance at 555 nm 
(Fig. 5). Best absorbance was accomplished when the 
sequence was in the order; drug, NBS, HCl, and then RB. 
This study is compatible and confirmed with the mechanism 
of reaction in Fig. 2.
Reagent and dye concentrations
Elementary experiments were achieved to fix the 
upper limits of RB dye that could be determined 
spectrophotometrically in acid medium and this was found 
to be 2.5 mL of 100 μg/mL of RB. This concentration 
gave stable and high intensity that was the reasonable 
concentration for this procedure.
A high concentration of oxidant NBS >100 μg/mL was 
found to destroy the color of RB dye. Under the experimental 
conditions, different volumes between 0.5 and 3.0 mL of 
Fig. 2. Mechanism of oxidation of captopril by excess NBS and the latest reaction with RB dye.
Fig. 3. Absorption spectra of (a) 2.5 mL of (100 μg/mL) rhodamine B, 
(b) 0.7 μg/mL captopril, 2.5 mL (100 μg/mL) of NSB and RB dye (c) 
blank reagent of 2.5 mL (100 μg/mL) of NSB and RB solution against 
distilled water.
TABLE II
Effect of temperature and heating time on the absorbance of RB dye
Temperature°C Absorbance
10 min 20 min 30 min 40 min 50 min 60 min
5 0.371 0.372 0.373 0.372 0.375 0.377
10 0.449 0.447 0.445 0.445 0.447 0.449
25 0.587 0.587 0.584 0.588 0.586 0.585
50 0.457 0.459 0.453 0.451 0.450 0.449
TABLE I
Amount of oxidant NBS solution for bleaching color of RB dye 
versus absorbance







NBS: n-bromosuccinimide, RB: Rhodamine B
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100 μg/mL NBS were examined (Table I). Therefore, 2.5 mL 
of NBS was adopted in the recommended procedure.
Effect of temperature and heating time
The redox reaction of 0.7 μg/mL captopril, 2.5 ml 
(100 μg/mL) NBS solution, and 2.5 mL (100 μg/mL) RB dye 
in 0.8 mL (1 mol/L) of HCl acidic medium was examined 
at various temperatures and heating times through measuring 
the absorbance (Table II).
As a general rule, increasing the temperature (5–25°C) 
will increase the reaction rate (for exothermic and 
endothermic) reactions simply because it means more 
energy available in the system. However, for the reversible 
exothermic reaction, there is a range of temperatures where 
this might not be true (Leenson, 1999). The absorbance 
was decreased as the temperature rose to 50°C. The 
results obtained in Table II may be understood in terms of 
increased quantum yield of the RB dye as the temperature 
is reduced (Ali, et al., 1991). A 25°C was then applied for 
further investigation.
Reaction time and stability of dye color
Time is a denoting factor on completing the redox reaction 
of 0.7 μg/mL captopril with 2.5 mL (100 μg/mL) NBS 
solution in 0.8 mL (1 mol/L) of HCl acidic medium and 
bleaching of 2.5 mL (100 μg/mL) RB dye. The maximum 
absorbance was attained after 10 min at 25 ± 2°C (Fig. 6). 
The color intensity of RB dye was stable after 25 min for at 
least 24 h at room temperature.
Interference studies
The effects of common excipients added in pharmaceutical 
preparations in the form of tablets and capsules were tested 
for their possible interferences in the assessment of captopril 
under optimum conditions (El-Didamony and Erfan, 2010). 
The excipient solutions (500 μg/mL) of lactose, fructose, 
glucose, starch, and sucrose were mixed with 0.7 μg/mL pure 
captopril in the final volume of 25 mL, individually. The 
spectra obtained were compared with the spectrum of 0.7 μg/
mL captopril standard solution. A level of interference was 
considered to be acceptable when the error is not higher than 
±5%. No significant levels of interferences were observed in 
the determination of captopril in the presence of the common 
excipients (Table III).
B. Analytical Figures of Merit
Determination of captopril was investigated under optimum 
experimental conditions, when the relative standard deviation 
(RSD%) was 2.33% as obtained from five replicated 
measurements of three different concentrations of captopril. 
In agreement with IUPAC guidelines of the validation of 
analytical method, the limit of detection value (LOD) = 3.3 
SD/P was adopted, in which SD is the standard deviation of 
Fig. 4. (a) Absorbance vs. solutions that contain 0.7 μg/mL captopril, 2.5 mL of (100 μg/mL) solution of each of NBS and RB dye with 1 mol/L of 
CH3COOH, HCl, H2SO4 and HNO3, individually; (b) Absorbance vs. solutions that contain 0.7 μg/mL captopril, 2.5 mL of (100 μg/mL) solution of 
each of NBS and RB dye with different volumes between (0.2-1.0 mL) of 1 mol/L HCl solution.
ba
Fig. 5. Absorbance of different sequence of mixing captopril, 2.5 mL 
(100 μg/mL) NBS, 2.5 mL (100 μg/mL) RB and 0.8 mL (1 mol/L) HCl 
solution.
TABLE IV
Accuracy and precision data for the proposed spectrophotometric 
indirect determination of captopril
Contained amount 
(μg/mL)
Found by proposed method 
(μg/mL)
SD RSD% E%*
0.3 0.305 0.002 2.030 1.66
0.7 0.690 0.005 0.920 -1.42
1.0 1.020 0.005 0.530 2.00
*Average of five determinations
TABLE III
Interference studies of captopril quantification toward some common 
excipients presented in the pharmaceutical products






* Average of three determinations
Fig. 6. Absorbance of 0.7 μg/mL captopril, 2.5 mL (100 μg/mL) NBS 
and 2.5 mL (100 μg/mL) RB solution in 0.8 mL (1 mol/L) of HCl acidic 
medium at different reaction times.
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Fig. 7. Calibration curve of spectrophotometric indirect quantitation of captopril via oxidant NBS and RB dye in acidic medium under optimum condition.
five reagent blank measurements and P is the gradient of the 
calibration curve (Topic Q2 (R1): Validation of Analytical 
Procedures: Text and Methodology, International Conference 
on Harmonization (ICH), 2005, Ana, et al., 2014, Tahir, 
et al., 2019). The linear range was 0.3–1.0 μg/mL with 
correlation coefficient R2 = 0.991 and molar absorptivity of 
2333 L/mol/cm (Fig. 7). The LOD and limit of quantification 
were 0.169 μg/mL and 0.304 μg/mL, respectively. The 
regression equation of standard solutions was Y = 1.0665x - 
0.1766 in which x is in μg/mL.
The accuracy and precision of the proposed procedure 
was provided by measuring the absorbance of RB dye after 
bleaching through excess amount of oxidant NBS that was 
remained after oxidation of three different concentrations of 
standard captopril (0.3, 0.7, and 1.0 μg/mL), individually in 
five replicate measurements (Table IV). The values of RSD 
% and E % were between 0.53%–2.03% and -1.42%–2.00%, 
respectively, indicating that the proposed procedure is valid 
and applicative.
C. Application and Comparison
The proposed procedure was successfully bestowed for 
the determination of captopril in pharmaceutical tables. 
The ingredients in the pharmaceutical tablets did not 
interfere in the quantification of captopril. The applicability 
of the proposed procedure for the analysis of captopril in 
pharmaceutical formulations was examined by investigating 
two pharmaceutical tablets and the results are shown in Table 
V which were compared to the standard captopril assay 
using HPLC method. HPLC has the capability to detach and 
determine compounds that are exist in any sample that can 
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TABLE V











E %* t and F values**
Captopril awa 25 25.34±1.13 25.02±0.14 101.27 1.27 t = 1.36, F = 1.78
Rilcapton 25 24.71±0.17 24.98±0.08 98.91 -1.08 t = 1.02, F = 1.98
*Average of five determinations, **Theoretical calculation of t and F at 95% confidence level (n=5) was 2.78 and 6.39, respectively, ***The values ± are the standard deviation of the 
five replication of each sample
be dissolved in a liquid in trace concentrations as low as 
parts per trillion (Iqbal, et al., 2015).
The performance of the proposed procedure was refereed 
by calculating the Student’s t- and F-values. At 95% 
confidence level, the calculated t- and F-values did not 
overstep the theoretical values as noticeable from Table V. 
Consequently, it was concluded that there is no significant 
difference between the proposed method and the standard 
method. Moreover, the spectrophotometric method for 
the determination of captopril in pharmaceutical tablets 
addressed in this work is simple, fast, inexpensive, precise, 
and accurate and it may be suitable for routine analysis and 
quality control laboratories.
In the literature, captopril was quantified using different 
oxidizing agents through spectrophotometric technique. 
Table VI views the optimization results of the determination 
of captopril using different reagent reactions and the 
proposed method. Despite that some analytical method have 
lower LOD value and wider linear range, but the proposed 
method does not need pre-extraction of the sample beside the 
easy and short time of the reaction.
IV. Conclusion
The proposed method has the expediency of simplicity and 
rapidity for the determination of captopril in both bulk and 
dosage forms and interferences free from common tablet 
excipients. The investigation method comprises less rigorous 
control of experimental parameters such as the stability of 
the colored reagent dye, time of reaction, and temperature 
independence. The reagents applied in the proposed method 
are low-priced, easily accessible and the procedure does not 
comprise any laborious sample preparation. These preferences 
boosted the application of the proposed method in routine 
quality control of captopril in industrial laboratories.
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